Compare Stocks: ICU vs. ADIL vs. AKTX vs. LSTA
Compare normalized stock price performance over 6 months, 1 year or 2 years. Each line starts at 0%, so different stock prices can be compared on the same scale.
ICUADILAKTXLSTA
Market Snapshot
Current market context for the selected companies.
ICU
$3.14
Market Cap
$14.01M
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
ADIL
$5.93
Market Cap
$15.28M
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
AKTX
$9.12
Market Cap
$15.32M
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
LSTA
$1.81
Market Cap
$15.68M
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
Performance
Absolute returns and relative performance versus SPY.
| Metric | ICU | ADIL | AKTX | LSTA |
|---|---|---|---|---|
| 1 Month | -8.7% | +101.2% | +8.2% | +56.0% |
| 1 Month vs SPY | -12.0% | +97.9% | +4.9% | +52.7% |
| 3 Months | -12.5% | +148.3% | -42.7% | -45.2% |
| 3 Months vs SPY | -14.5% | +146.3% | -44.7% | -47.2% |
| 6 Months | +27.1% | +143.2% | -12.6% | -58.8% |
| 6 Months vs SPY | +16.7% | +132.8% | -23.1% | -69.2% |
| 1 Year | -64.7% | -37.5% | -74.2% | -28.5% |
| 1 Year vs SPY | -83.8% | -56.7% | -93.4% | -47.6% |
| 2 Years | -94.9% | -75.8% | -93.6% | -38.6% |
| 2 Years vs SPY | -131.5% | -112.3% | -130.2% | -75.2% |
Growth & Profitability
Operating growth, margins and capital efficiency.
Valuation
Common valuation multiples shown side by side.
Cash Flow & Balance Sheet
Cash generation and leverage context.
Earnings Outlook
Upcoming earnings expectations when available.